Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

CELG / Celgene Corp. EXHIBIT 5.1

3h sec.gov
Exhibit 5.1   Proskauer Rose LLP   Eleven Times Square   New York, NY 10036-8299   February 20, 2018 Celgene Corporation 86 Morris Avenue Summit, NJ 07901   Ladies and Gentlemen:   We have acted as special counsel for Celgene Corporation, a Delaware corporation (the “Company”), with respect to the preparation of the Registration Statement on Form S-3 (the “Registration Statement”) filed on October 27, 2016 with the Securities and Exchange Commission (the “Commission”) in connection with the regi (54-0)

CELG / Celgene Corp. EXHIBIT 4.5

3h sec.gov
  Exhibit 4.5   Form of 4.550% Senior Note due 2048   GLOBAL SECURITY   THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY. THIS NOTE IS EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE (54-0)

CELG / Celgene Corp. EXHIBIT 4.4

3h sec.gov
  Exhibit 4.4   Form of 3.900% Senior Note due 2028   GLOBAL SECURITY   THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY. THIS NOTE IS EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE (54-0)

CELG / Celgene Corp. EXHIBIT 4.3

3h sec.gov
  Exhibit 4.3   Form of 3.250% Senior Note due 2023   GLOBAL SECURITY   THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY. THIS NOTE IS EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE (54-0)

CELG / Celgene Corp. EXHIBIT 4.2

3h sec.gov
  Exhibit 4.2   Form of 2.875% Senior Note due 2021   GLOBAL SECURITY   THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY. THIS NOTE IS EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE (54-0)

CELG / Celgene Corp. EXHIBIT 4.1

3h sec.gov
  Exhibit 4.1   CELGENE CORPORATION,   as Issuer,   and   The Bank of New York Mellon Trust Company, N.A.,   as Trustee   INDENTURE   Dated as of February 20, 2018          CROSS-REFERENCE TABLE   TIA Section   Indenture Section         310 (a)(1)   8.9   (a)(2)   8.9   (a)(3)   N/A   (a)(4)   N/A   (a)(5)   8.9   (b)   8.8; 8.9   (c)   N/A 311 (a)   8.13   (b)   8.13   (c)   N/A 312 (a)   9.1   (b)   9. (54-0)

CELG / Celgene Corp. FORM 8-K (Current Report)

3h sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): February 20, 2018       CELGENE CORPORATION (Exact name of registrant as specified in its charter)       Delaware 001-34912 22-2711928 (State or other jurisdiction  of incorporation) (Commission File Number) (IRS Employer Identification No. (54-0)

Biotechs: Still Well Placed For More Gains

5h seekingalpha
Big Pharma has to build out pipelines in new areas, and M&A is a compelling alternative. (719-2)

What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?

8h zacks
Juno Therapeutics Inc. (JUNO - Free Report) is expected to report fourth-quarter 2017 results on Mar 7, after the market closes. Last quarter, the company delivered a positive earnings surprise of 10.98%. (106-0)

Pharmaceutical Titan’s Senate Bid Will Test Voters’ Views on Drug Prices - Bloomberg

11h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (62-0)

Healthcare In Transition

2018-02-19 seekingalpha
With policy changes, integration, and the introduction of technology, healthcare is transforming and stands at a very pivotal point in America. (830-2)

Celgene Reports Positive Data on Dermatology Drug Otezla

2018-02-19 zacks
Celgene Corporation (CELG - Free Report) announced data from phase III trial, RELIEF, on dermatology drug Otezla in a late-breaking oral presentation at the 2018 American Academy of Dermatology ("AAD") Annual Meeting. (128-0)

Your Daily Pharma Scoop: AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Celgene Reports Results For Otezla

2018-02-19 seekingalpha
Today we will discuss AbbVie (ABBV), which continues to have a phenomenal run in 2018 even as sentiment on the broader equity market has turned negative. (144-0)

Merger And Acquisition: What Can Investors Learn From The Seattle Genetics Buyout Of Cascadian?

2018-02-18 seekingalpha
This M&A satisfied 50% of our criteria conducive to a buyout. For one, there is pipeline synergy. (107-1)

Is Celgene A Growth Or A Value Stock?

2018-02-17 seekingalpha
Traded as a value company, Celgene does not appear to convincingly show a long-term vision typical for growth companies. (134-3)


CUSIP: 151020104